Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PIMECROLIMUS vs ABLYSINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.
Mild to moderate atopic dermatitis in immunocompetent patients aged 2 years and older,Off-label: psoriasis, seborrheic dermatitis, vitiligo, lupus erythematosus
Empiric therapy for presumed fungal infection in febrile neutropenic patients,Treatment of systemic fungal infections (e.g., aspergillosis, candidiasis, cryptococcosis),Treatment of visceral leishmaniasis
Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.
Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.
Terminal elimination half-life is approximately 65 hours (range 22–115 hours) in adult atopic dermatitis patients, reflecting slow systemic clearance.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; prolonged to 12–24 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized via hepatic cytochrome P450 3A4 (CYP3A4) to O-demethylated metabolites; also undergoes further hydroxylation and glucuronidation.
Ivermectin is metabolized primarily by CYP3A4 to hydroxylated and demethylated metabolites. Phase II glucuronidation may occur. No active metabolites are identified.
Primarily fecal (78.4% of dose) via biliary excretion; renal elimination accounts for <1% of unchanged drug.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; the remaining 10% is metabolized.
99.5% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 85% bound to serum albumin and alpha-1-acid glycoprotein.
Approximately 1.3 L/kg (range 0.6–2.1 L/kg), indicating extensive tissue distribution.
Volume of distribution is 0.5 L/kg, indicating distribution primarily into extracellular fluid.
Topical: Systemic bioavailability is very low (<0.5% of applied dose) based on blood concentration measurements.
Oral bioavailability is 40–50% due to first-pass metabolism; intramuscular bioavailability is 80%.
No dose adjustment required for renal impairment; systemic absorption is minimal (<2.5%).
GFR ≥30 m L/min: no adjustment; GFR <30 m L/min: not recommended.
No formal studies in hepatic impairment; based on minimal systemic absorption, no adjustment is likely required, but use caution in severe hepatic impairment due to theoretical risk of increased exposure.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated.
Children ≥2 years: Apply a thin layer of 1% cream to affected areas twice daily; maximum application area: <20% body surface area. Avoid use in children <2 years due to risk of systemic effects (insufficient data).
Not approved for use in pediatric patients.
No specific dose adjustment; use lowest effective amount due to potential for increased skin sensitivity and renal function decline with age.
No specific dose adjustment; monitor for increased sensitivity and renal function.
Long-term safety of topical calcineurin inhibitors has not been established; rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported; avoid continuous long-term use; limit use to indicated short-term and intermittent treatment.
This drug should be used primarily for treatment of progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of disease (e.g., oral thrush, vaginal candidiasis).
Increased risk of infections (e.g., varicella zoster, herpes simplex); avoid use on active infections; possible lymphadenopathy; photosensitivity (avoid UV exposure); monitor for skin atrophy; not recommended in children <2 years; use during pregnancy only if clearly needed.
Monitor renal function closely; may cause dose-dependent nephrotoxicity. Premedicate for infusion reactions (fever, chills, rigors). Monitor electrolytes (hypokalemia, hypomagnesemia). Risk of cardiotoxicity with rapid infusion. Use caution in patients with renal impairment; dose adjustment required.
History of hypersensitivity to pimecrolimus or any component of the formulation; Netherton syndrome; generalized erythroderma; active viral, bacterial, or fungal skin infections at application site.
Hypersensitivity to amphotericin B or any component of the formulation, unless the benefit outweighs the risk.
No known food interactions with topical pimecrolimus. Oral ingestion should be avoided; however, accidental small amounts on skin are unlikely to cause systemic effects.
Avoid grapefruit and grapefruit juice as they may increase fingolimod concentrations. No specific dietary restrictions, but maintain adequate hydration.
Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: theoretical risk due to systemic absorption; avoid if possible. Second and third trimesters: limited data; risk of fetal harm cannot be excluded.
Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, premature closure of ductus arteriosus, and neonatal renal impairment.
It is not known whether pimecrolimus is excreted in human milk. Systemic absorption after topical application is minimal (<2.5 ng/m L), suggesting negligible transfer. However, due to potential for serious adverse reactions in nursing infants, caution should be exercised. M/P ratio is not available. Breastfeeding is generally considered acceptable with cautious use.
Contraindicated. Excreted in human milk; M/P ratio not determined. Potential for serious adverse reactions in breastfed infants.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy. Use the minimum amount necessary to control symptoms, and avoid application to large body surface areas or prolonged use. Systemic absorption is minimal and unlikely to be altered significantly during pregnancy.
Increased renal clearance in pregnancy may require dose increments of 30-50% to maintain therapeutic levels; monitor serum lithium concentrations and adjust dose to therapeutic range (0.6-1.2 m Eq/L).
Pimecrolimus is a topical calcineurin inhibitor used for mild-to-moderate atopic dermatitis. It is not indicated for use in children under 2 years. Avoid use on infected skin; monitor for local irritation. Long-term safety concerns include potential increased risk of lymphoma and skin malignancies; use minimal amounts for shortest duration necessary. Do not use with occlusive dressings. Consider intermittent therapy for flares.
ABLYSINOL (fingolimod) is a sphingosine-1-phosphate receptor modulator used for relapsing forms of multiple sclerosis. First-dose monitoring for bradycardia (6 hours) is mandatory; consider pre-treatment ECG. Avoid live vaccines during and for 2 months after therapy. Monitor for macular edema (ophthalmologic exam at baseline and 3-4 months). Lymphopenia is expected; check CBC before initiation and periodically. Drug interactions: QTc-prolonging agents, immunosuppressants, beta-blockers, calcium channel blockers. Do not use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias.
Apply a thin layer only to affected areas, avoiding eyes, mouth, and broken skin.,Do not cover treated area with bandages or wraps unless directed by your doctor.,Wash hands after applying unless treating hands.,Avoid sun exposure, tanning beds, and UV therapy while using this medication.,Report any signs of infection, skin burning, or worsening rash.,Do not use for prolonged periods; use only until symptoms clear.,Inform your doctor if you are pregnant, breastfeeding, or have a weakened immune system.
Stay hydrated and avoid grapefruit juice; it may increase drug levels.,Report any vision changes, slow heartbeat, or dizziness immediately.,Avoid pregnancy; use effective contraception during and for 2 months after stopping.,Do not receive live vaccinations during treatment.,Take exactly as prescribed; do not skip doses or stop suddenly.
"Pimecrolimus, a calcineurin inhibitor, and panobinostat, a histone deacetylase inhibitor, both have immunosuppressive and potential myelosuppressive effects. Concurrent use may synergistically increase the risk of infections, including opportunistic infections, and hematologic toxicities such as neutropenia, thrombocytopenia, and anemia. Additionally, both drugs can prolong the QT interval, potentially increasing the risk of serious cardiac arrhythmias like torsade de pointes."
"Pimecrolimus, a calcineurin inhibitor used topically, can inhibit CYP3A4 activity to a mild degree, potentially decreasing the metabolism of nilotinib, a BCR-ABL tyrosine kinase inhibitor that is predominantly metabolized by CYP3A4. This may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, hepatotoxicity, and other dose-related adverse effects. Therefore, patients should be carefully monitored for signs of nilotinib toxicity."
"Pimecrolimus and sirolimus both suppress immune function via distinct but overlapping mechanisms. Pimecrolimus inhibits calcineurin, reducing T-cell activation, while sirolimus inhibits mTOR, blocking cytokine-driven T-cell proliferation. Concomitant use increases the risk of over-immunosuppression, leading to higher susceptibility to infections, lymphoproliferative disorders, and possibly nephrotoxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PIMECROLIMUS vs ABLYSINOL, answered by our medical review team.
PIMECROLIMUS is a Calcineurin Inhibitor that works by Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.. ABLYSINOL is a Calcineurin inhibitor that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PIMECROLIMUS and ABLYSINOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PIMECROLIMUS is: Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.. The standard adult dose of ABLYSINOL is: Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PIMECROLIMUS and ABLYSINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PIMECROLIMUS is classified as Category A/B. Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no. ABLYSINOL is classified as Category C. Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.